The Report and Its Timeline
The IEEE Future Directions Committee’s Industry Advisory Board released its 2030 Technology Megatrends Report on October 7. The document forecasts that genetic engineering and gene therapy will move from experimental stages to frequent clinical use by 2028. Artificial intelligence supplies the analytical speed required to match patient genetics to therapies at scale. IEEE Fellow Dejan Milojicic, who chairs the advisory board, described the change as a shift in which AI no longer operates separately from physical systems.
The report groups thirty individual technologies under five megatrends. Each megatrend represents a change large enough to alter daily infrastructure or medical practice. Prior IEEE reports treated AI, energy systems, and biotechnology as parallel tracks. This edition collapses those tracks and ties AI progress directly to the projected speed of gene-therapy adoption.
Specifics on the Forecast
The report credits advances in AI for the 2028 deadline. Algorithms can now process genomic datasets at scales that support identification of viable edits for multiple disease categories. Milojicic, a Hewlett Packard Enterprise Fellow and vice president at HPE Labs in Milpitas, California, stated that “Artificial intelligence is no longer operating in a vacuum; it is now deeply connected to our energy, infrastructure, and physical systems.” He also said, “We are seeing a fundamental shift in how technology evolves.”
AI underpins many of the thirty technologies listed. The five megatrends are defined as technology shifts with the potential to reshape established domains. The report presents the thirty technologies only as examples that sit beneath those megatrends. No competing forecasts from other organizations appear in the release.
Reactions and Scope
No counter-forecasts or dissenting views from other bodies are included in the IEEE materials. The emphasis remains on the integration of AI with physical domains as the driver of the gene-therapy timeline rather than any isolated medical breakthrough.
Why it Matters
For engineers and product teams, the report removes the assumption that AI work stays inside data centers. Any system that touches physical infrastructure or medical delivery must now account for AI models that directly influence hardware design, energy budgets, and regulatory pathways. Gene-therapy pipelines will require tighter integration between genomic databases, compute clusters, and hospital equipment. Teams that continue to treat these domains as separate will face longer qualification times once the 2028 window opens.
The concrete prediction supplies a fixed date against which engineering road maps can be measured. Organizations planning compute resources for genomic analysis can align capacity additions with the same horizon. Hardware designers working on sequencing instruments or delivery devices gain a shared timeline with AI model developers. Regulatory groups preparing review processes for gene therapies can anticipate data volumes and decision speeds that AI enables rather than manual review alone.
The linkage also affects energy planning. Because the report places AI inside energy and infrastructure megatrends, power budgets for large-scale genomic computation become part of the same conversation as therapy deployment. Facilities that host both compute and clinical operations must size cooling and grid connections with the combined load in mind. This integration changes capital planning cycles that previously treated medical equipment and data-center expansions as independent projects.
Road-map owners at semiconductor firms, cloud providers, and hospital networks now have a single external reference point. They can test internal assumptions against the 2028 date instead of waiting for later consensus documents. The report does not detail every technology beneath the megatrends, yet the explicit medical deadline gives teams a measurable target for integration work that must finish before routine clinical use begins.
---
Sources:
No comments yet